Glaxo’s new Covid-19 booster vaccine shows positive results in trials

Posted on

Shot in the arm for Glaxo as trials of agency’s new Covid-19 booster vaccine present encouraging results

GlaxoSmithKline acquired a dose of fine news after its Covid-19 booster vaccine developed alongside French group Sanofi generated a powerful immune system response in medical trials.

The two companies are main vaccine makers however fell behind in the race to develop a Covid-19 jab.

However, Sanofi stated knowledge from two trials confirmed the jab offered a ‘significant boost’ in antibodies towards a number of variants of the virus in sufferers who had beforehand acquired mRNA vaccines reminiscent of these made by US rivals Pfizer and Moderna.

On level: GlaxoSmithKline has teamed up with French group Sanofi after falling behind in the race to develop Covid vaccines

The French agency added that the jab offered the next immune system response than a Pfizer booster and in addition demonstrated potential to guard towards the Omicron variant.

‘Covid-19 keeps evolving and the combination of emergence of variants and waning immunity is likely to lead to the need for additional booster shots,’ stated Thomas Triomphe, govt vp of Sanofi’s vaccine division.

‘We believe this next-generation booster could have an important role to play for public health vaccination campaigns.’

Investors remained unimpressed, nonetheless, and GSK shares closed flat at 1736p.

Advertisement

money/markets/article-10912845/Glaxos-new-Covid-19-booster-vaccine-shows-positive-results-trials.html?ns_mchannel=rss&ns_campaign=1490&ito=1490″>Source Article

Leave a Reply

Your email address will not be published.